Fluticasone Exhalation Delivery System Reduced Exacerbations, Need for Antibiotics in Patients with Chronic Sinusitis
October 24, 2022

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

Chronic Sinusitis Flares Reduced by 66% in Pooled Analysis of Optinose ReOpen Program Data
July 13, 2022

For patients with chronic sinusitis, disease exacerbations often require use of antibiotics and steroids, in addition to medical office visits, all of which impact quality of life.

FDA Approved Dupilumab as the First Treatment for Eosinophilic Esophagitis
May 23, 2022

Dupilumab is approved for the treatment of eosinophilic esophagitis in patients aged ≥12 years weighing at least 40 kgs.

7 New Drugs Approved for Primary Care: Q1 2022
April 07, 2022

Another new COVID-19 vaccine, the first and only once-daily amphetamine transdermal patch approved for the treatment of ADHD, and 5 more.

Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
March 03, 2022

Tara Carr, MD, led a post hoc analysis of the NAVIGATOR phase 3 trial and presented data on tezepelumab efficacy in the vulnerable subgroup at the AAAAI 2022 meeting.

Novel Agent for Severe Asthma Halves Exacerbation Rates Across Respiratory Comorbidities
February 28, 2022

Tezepelumab, a TSLP inhibitor, reduced asthma exacerbation rates in patients with severe uncontrolled disease across a range of respiratory comorbidities.

Dupilumab Significantly Decreased Itch and Hives in Patients with Chronic Spontaneous Urticaria
February 26, 2022

Dupilumab significantly reduced itch and hives in patients with H1 antihistamine-resistant chronic spontaneous urticaria, according to new research.

Severe Asthma Research Recap: 8 Updates for Primary Care
February 16, 2022

Research summaries on GINA revisions, a steroid-reduction algorithm, factors that predict asthma exacerbation risk, and more.

Severe Asthma Endotypes: A Test on Features, Assessment & Treatment
February 08, 2022

How familiar are you with mechanistic features of severe asthma, specific biomarker level cut offs, and impact of comorbid disease on choice of biologic treatment?

Severe Uncontrolled Asthma: 5 Questions on Key Characteristics
February 08, 2022

Optimal use of biologic therapy for severe uncontrolled asthma rests on understanding of the disease itself. Try this quick quiz to test your knowledge.